A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.
Liver Concerns Foil GLP-1 Drug; Not Enough Menopause Training; Wegovy Supply Limits
Pfizer dropped development of lotiglipron, its investigational GLP-1 receptor agonist for obesity, due to elevated liver enzymes; could other agents in the drug class carry